VR Logo

Passage Bio Inc. (PASG) download report


Healthcare | Biotechnology & Pharma Research

Passage Bio Inc. (PASG) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.

IPO Date: 28-Feb-2020

CEO, Pres & Director: Dr. Bruce A. Goldsmith M.B.A., Ph.D.

Co-Founder & Chief Scientific Advisor: Dr. James M. Wilson M.D., Ph.D.

Listing: NASDAQ: PASG

Country: United States

Headquarters: Philadelphia, PA

Website: https://www.passagebio.com

Key Facts

Market cap: $129.25 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-189.32 Mln

Cash: $267.09 Mln

Total Debt: $27.55 Mln

Insider's Holding: 9.75%

Liquidity: Low

52 Week range: $1.57 - 16.14

Shares outstanding: 54,307,700

Stock Performance

Time Period Passage Bio (PASG) S&P BSE Sensex* S&P Small-Cap 600*
YTD-62.52-8.62-18.78
1 month27.96-4.54-8.00
3 months-23.23-10.19-13.65
1 Year-82.021.43-17.19
3 Years--10.146.10
5 Years--11.265.87
10 Years--11.829.84
As on 01-Jul-2022 *As on 04-Jul-2022
Year Passage Bio (PASG) S&P Small-Cap 600 S&P BSE Sensex
2021-75.1725.2721.99